Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.130
-0.020 (-1.74%)
At close: Apr 28, 2026, 4:00 PM EDT
1.120
-0.010 (-0.88%)
After-hours: Apr 28, 2026, 5:48 PM EDT
Entera Bio Revenue
In the year 2025, Entera Bio had annual revenue of $42.00K, down -76.80%.
Revenue (ttm)
$42.00K
Revenue Growth
-76.80%
P/S Ratio
1,276.56
Revenue / Employee
$1,909
Employees
22
Market Cap
51.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.00K | -139.00K | -76.80% |
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 43.77M |
| Metagenomi Therapeutics | 25.21M |
| Radiopharm Theranostics | 10.86M |
| Nutriband | 2.28M |
| Hyperion DeFi | 813.46K |
ENTX News
- 8 days ago - BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity - GlobeNewsWire
- 8 days ago - Entera Bio Transcript: KOL event - Transcripts
- 14 days ago - Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 - GlobeNewsWire
- 22 days ago - Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners - PRNewsWire
- 26 days ago - Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds - GlobeNewsWire
- 4 weeks ago - Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - GlobeNewsWire
- 2 months ago - Entera Bio Announces Open Market Purchases of Company Stock by Board Members - GlobeNewsWire